Rare lephants
Screener

AIM IMMUNOTECH INC.

AIM ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — AIM ImmunoTech Inc.

Total Moat Score 5 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 59 issued patents plus 71 pending, and FDA/EMA Orphan Drug Designations for Ampligen across several indications, provide genuine IP and regulatory-exclusivity protection despite pre-commercial status.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 As a small, cash-constrained clinical-stage biotech, AIM has no cost advantage versus large pharmaceutical competitors running similar trials.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Ampligen's Argentina approval and orphan status could eventually support premium specialty-drug pricing, but with minimal current revenue this is entirely prospective.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 A pharmaceutical drug candidate business generates no network effects.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Once physicians and patients are established on Ampligen through the expanded-access ME/CFS program, there is modest continuity/switching friction, but this is a small program, not a broad commercial base.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 0 / 5 Oncology and antiviral drug development attracts intense competition from far larger, better-funded pharmaceutical companies; the space is not protected by limited scale.